Why did Abivax shares drop after strong obefazimod phase 3 results?

Despite reporting high clinical remission rates for obefazimod in ulcerative colitis, Abivax’s stock fell because several patients on the 50 mg dose developed cancers. The unexpected malignancies raised new safety concerns and investor uncertainty, offsetting enthusiasm over the drug’s strong efficacy and delaying potential partnership or acquisition talks.